Moderna (MRNA) Q4 2024 Earnings Call Transcript
Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
‘Personalized, unrestricted’ AI lab Nous Research launches first toggle-on reasoning model: DeepHermes-3
One DeepHermes-3 user reported a processing speed of 28.98 tokens per second on a MacBook Pro M4 Max consumer hardware.
Earnings call transcript: Moderna Q4 2024 sees revenue drop, market reacts
Moderna Inc . (BMV:MRNA) reported its fourth-quarter earnings for 2024, revealing a significant decline in revenue and a net loss. The company's earnings per share (EPS) were lower than expected, and ...